Supernus Pharmaceuticals Inc.

06/18/2026 | Press release | Distributed by Public on 06/18/2026 14:56

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 18, 2026 Supernus Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The definitive proxy statement pertaining to the Annual Meeting was previously filed by the Company with the Securities and Exchange Commission on April 30, 2026. As of the close of business on April 29, 2026, there were 58,039,721 shares of common stock outstanding and entitled to vote. The tabulation of votes for each proposal voted on by the stockholders was as follows:
Proposal 1: Election of Class I Directors, each to serve until the Annual Meeting of the Company in 2029.
Name Votes For Votes Withheld Broker Non-Votes
Frederick M. Hudson 45,058,634 2,177,068 3,073,181
Charles W. Newhall, III 41,743,154 5,492,548 3,073,181
Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.
Votes For Votes Against Abstain Broker Non-Votes
45,552,633 1,675,355 7,714 3,073,181
Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026.
Votes For Votes Against Abstain Broker Non-Votes
49,882,228 417,336 9,319 0
Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the "Plan") to increase the number of shares available under the Plan.
Votes For Votes Against Abstain Broker Non-Votes
41,925,692 5,302,088 7,922 3,073,181
Supernus Pharmaceuticals Inc. published this content on June 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 18, 2026 at 20:56 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]